Japan Oncology Drugs Market 2019 Analysis & Biggest Innovation by Leading Key Players : Sanofi, Amgen Inc., Bayer AG

According to a new report published, titled, "Japan Oncology Drugs Market by Drug Class Type, and Indication: Opportunity Analysis and Industry Forecast, 2019-2026," the Japan oncology drugs market accounted for $9,405 million in 2018, and is expected to reach $14,109 million by 2026, registering a CAGR of 5.2% from 2019 to 2026.

Cancerous cells are formed when the normal cells present in the body grow at an uncontrolled rate. This abnormal growth leads to the formation of a tumor which can spread to other localized tissues. Moreover, cancer has different stages based on the growth of tumor. Metastasis is the final stage of the disease, which is marked by the invasion of tumor in other parts of the body. The management of cancer in patients requires the use of different drugs such as hormonal therapy, immunotherapy, targeted therapy, and others.

Get Free Sample PDF Brochure Here@ https://www.qurateresearch.com/report/sample/HnM/japan-oncology-drugs-market/QBI-AMR-HnM-515830

Factors such as rise in incidence of cancer in Japan, increase in healthcare expenditure and surge in research related to new drug discovery for cancer treatment in the region are the major factors that boost the growth of Japan oncology drugs market. Furthermore, surge in geriatric population also contributes to the growth of the market as the elderly are more prone to certain cancer such as prostate cancer. Moreover, surge in awareness related to early diagnosis of cancer leading to rise in demand of oncology drugs for treatment is another factor that fuels the growth of the market in Japan. In addition, rise in number of pipeline products is expected to provide lucrative opportunities during the forecast period. However, stringent approval process of oncology drugs in Japan hinders the growth of market

The Japan oncology drugs market is segmented on the basis of drug class type and indication. Based on drug class type, the market is divided into chemotherapy, targeted therapy, immunotherapy, hormonal therapy. By indication, it is categorized into blood cancer, breast cancer, gastrointestinal cancer, prostate cancer, lung cancer, skin cancer, ovarian cancer, cervical cancer, kidney cancer and others.

Depending on drug class type, the targeted therapy segment occupied the largest share of Japan oncology drugs market in 2018. This is attributed to lesser side effects of the targeted therapy drugs as compared to other treatment options. Targeted therapies have the ability to kill only malignant cells thereby exhibiting better treatment outcomes which fuel the growth of market. In addition, higher efficacy and higher survival rates associated with the use of targeted therapy drugs are other reasons that fuel the growth of the market.

Get Flat 15% Discount on this Report@ https://www.qurateresearch.com/report/discount/HnM/japan-oncology-drugs-market/QBI-AMR-HnM-515830

LIST of OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)

•Sanofi

•Amgen Inc.

•Bayer AG

Furthermore, immunotherapy segment is expected to show fastest growth during the forecast period. This is due to wide acceptance of immunotherapy drugs as an ideal treatment option for cancer. Immunotherapy drugs are ideal treatment options as these drugs are potentially harmless to the other living cells of the body which makes them less toxic as compared to other modes of cancer therapies. Moreover, continuous efforts in R&D to design and develop new immunotherapeutic for the treatment of various cancer types serves as a key factor for market growth.

Based on indication, the prostate cancer segment occupied the largest share of market in 2018 owing to the presence of huge geriatric population. However, lung cancer segment is expected to show fastest growth during the forecast period attributed to technological developments in the field of cancer diagnostics and rise in the awareness related to the early diagnosis of cancer.
According to our research analyst, “Surge in prevalence of cancer is anticipated to significantly drive the growth of the Japan oncology drugs market. Furthermore, rise in geriatric population, increase in healthcare expenditure, and upsurge in awareness related to early screening of cancer are the key factors that augment the market growth.”

Purchase Full Research Report@ https://www.qurateresearch.com/report/buy/HnM/japan-oncology-drugs-market/QBI-AMR-HnM-515830

Reasons to Purchase Japan Oncology Drugs Market Report:

Analyzing the outlook of the Japan Oncology Drugs market with the recent trends and SWOT analysis.
Market dynamics scenario, along with growth opportunities of the Japan Oncology Drugs market in the years to come.
Japan Oncology Drugs Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and non-economic aspects.
Regional and country level analysis integrating the demand and supply forces that are influencing the growth of Japan Oncology Drugs market.
Japan Oncology Drugs Market value (USD Million) and volume (Units Million) data for each segment and sub-segment.
Competitive landscape involving the Japan Oncology Drugs market share of major players, along with the new projects and strategies adopted by players in the past 5 year.
Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major Japan Oncology Drugs market players.

Contact Us:
Nehal Chinoy
Runwal Platinum,
Ramnagar Colony, Bavdhan,
Pune, Maharashtra, India-411021
IN +919881074592
info@qurateresearch.com
https://www.qurateresearch.com/

About Us:
Qurate Business Intelligence delivers unique market research solutions to its customers and help them to get equipped with refined information and market insights derived from reports. We are committed to providing best business services and easy processes to get the same. Qurate Business Intelligence considers themselves as strategic partners of their customers and always shows the keen level of interest to deliver quality.

This release was published on openPR.